https://www.avient.com/sites/default/files/2022-12/Mevopur Colors for Ophthalmic Closures Application Bulletin_A4.pdf
KEY CHARACTERISTICS
• Manufactured at four ISO 13485 certified
manufacturing sites, providing global
consistency and increased security of supply
• Documented change control beyond CAS
number, reducing risk of change
• Non-phthalate and formulated without animal-
derived substances
• Standard concentrates in a PE carrier and
on request in PP
• Pre-colored formulations can be supplied in
specific resins selected for the application
REGULATORY SUPPORT
• Raw materials tested to:
- ISO 10993-1 and USP biological
evaluation
- European Pharmacopeia 3.1.3/3.1.5
(polyolefin)
- USP (polyethylene)
- ICH Q3D elemental impurities
• Registered Drug Master File (Type III)
• Food contact established with FDA/EU*
APPLICATION BULLETIN
DRUG TYPE COLOR DESCRIPTION
PANTONE
REFERENCE
AVIENT PRODUCT
CODE PE BASED
Adrenergic agonist
combinations
Light Green 373 C PE6M176349
Adrenergic agonists Purple 2583 C PE4M176057
Anti-infectives Tan 467 C PE8M176130
Anti-inflammatory,
nonsteroidal
Grey Cool Grey 4 C PE7M176184
Anti-inflammatory,
steroids
Pink 197 C PE3M176237
Anti-inflammatory,
immunomodulators
Olive Green 5763 C On request
Beta-blockers Yellow Yellow C PE1M176160
Beta-blocker combinations Dark Blue 281 C PE5M176272
Carbonic anhydrase inhibitors Orange 1585 C PE2M176089
Cytotoxic Black 6 C PL9M176008
Miotics Dark Green 348 C PE6M176267
Mydriatics and cycloplegics Red 1797 C PE3M176236
Prostaglandin analogues Turquoise 326 C PE5M176273
Healthcare use limitations apply—see below.
https://www.avient.com/sites/default/files/2022-09/Avient Discontinued Operations Financial Information.pdf
Microsoft PowerPoint - Avient Discontinued Operations Financial Information
AVIENT CORPORATION
R E C A S T F I N A N C I A L I N F O R M A T I O N T O
R E F L E C T D I S T R I B U T I O N A S A
D I S C O N T I N U E D O P E R A T I O N
(NYSE: AVNT)
S E P T E M B E R 2 7 , 2 0 2 2
TAB LE OF CONTENTS
Avient Corporation 2
Slide 3 - GAAP Income Statement Recast for Avient Distribution as a Discontinued Operation
Reflects US GAAP (GAAP) Income Statements recast for Avient Distribution as a discontinued operation.
G A A P I N C O M E S T A T E M E N T R E C A S T F O R A V I E N T D I S T R I B U T I O N A S A
D I S C O N T I N U E D O P E R A T I O N
Avient Corporation 3
(In millions, except per share data)
Q1 2021 Q2 2021 Q3 2021 Q4 2021 2021 YTD Q1 2022 Q2 2022 YTD 2022
Sales 826.0$ 864.5$ 818.0$ 807.1$ 3,315.6$ 892.2$ 891.0$ 1,783.2$
Cost of sales 562.9 615.9 602.4 590.5 2,371.7 637.8 630.1 1,267.9
Gross margin 263.1 248.6 215.6 216.6 943.9 254.4 260.9 515.3
Selling and administrative 168.7 166.2 162.8 166.4 664.1 152.2 160.8 313.0
Operating income 94.4 82.4 52.8 50.2 279.8 102.2 100.1 202.3
Interest expense, net (19.3) (19.5) (19.0) (17.5) (75.3) (16.9) (16.2) (33.1)
Other income (expense), net 1.6 1.1 1.6 (5.3) (1.0) (0.6) 1.6 1.0
Income before income taxes 76.7 64.0 35.4 27.4 203.5 84.7 85.5 170.2
Income tax (expense) benefit (16.3) (13.8) (2.0) (16.2) (48.3) (20.0) (22.7) (42.7)
Net income from continuing operations 60.4 50.2 33.4 11.2 155.2 64.7 62.8 127.5
Net income from discontinued operations, net of income taxes 19.3 19.2 19.2 17.7 75.4 19.8 21.9 41.7
Net income 79.7 69.4 52.6 28.9 230.6 84.5 84.7 169.2
Net (income) loss attributable to noncontrolling interests (0.4) (0.6) 0.3 0.9 0.2 (0.3) - (0.3)
Net income attributable to Avient common shareholders 79.3$ 68.8$ 52.9$ 29.8$ 230.8$ 84.2$ 84.7$ 168.9$
Earnings per share attributable to Avient common shareholders - Basic
Continuing operations 0.66$ 0.54$ 0.37$ 0.13$ 1.70$ 0.70$ 0.69$ 1.39$
Discontinued operations 0.21$ 0.21$ 0.21$ 0.20$ 0.83$ 0.22$ 0.24$ 0.46$
Total 0.87$ 0.75$ 0.58$ 0.33$ 2.53$ 0.92$ 0.93$ 1.85$
Earnings per share attributable to Avient common shareholders - Diluted
Continuing operations 0.65$ 0.54$ 0.37$ 0.13$ 1.69$ 0.70$ 0.68$ 1.38$
Discontinued operations 0.21$ 0.20$ 0.20$ 0.19$ 0.82$ 0.21$ 0.24$ 0.45$
Total 0.86$ 0.74$ 0.57$ 0.32$ 2.51$ 0.91$ 0.92$ 1.83$
A D J U S T E D F I N A N C I A L I N F O R M A T I O N R E C A S T F O R A V I E N T D I S T R I B U T I O N A S A
D I S C O N T I N U E D O P E R A T I O N
Avient Corporation 4
(In millions, except per share data)
Q1 2021 Q2 2021 Q3 2021 Q4 2021 2021 YTD Q1 2022 Q2 2022 YTD 2022
Sales 826.0$ 864.5$ 818.0$ 807.1$ 3,315.6$ 892.2$ 891.0$ 1,783.2$
Cost of sales 565.1 603.3 585.1 584.6 2,338.1 632.0 632.1 1,264.1
Gross margin 260.9 261.2 232.9 222.5 977.5 260.2 258.9 519.1
Selling and administrative 164.1 164.6 160.1 161.1 649.9 151.3 157.0 308.3
Operating income 96.8 96.6 72.8 61.4 327.6 108.9 101.9 210.8
Interest expense, net (19.3) (19.5) (19.0) (17.5) (75.3) (16.9) (16.2) (33.1)
Other income (expense), net 1.6 1.1 1.5 4.1 8.3 (0.7) 0.7 0.0
Income before income taxes 79.1 78.2 55.3 48.0 260.6 91.3 86.4 177.7
Income tax expense (16.1) (16.3) (10.2) (12.8) (55.4) (20.2) (20.4) (40.6)
Net income from continuing operations 63.0 61.9 45.1 35.2 205.2 71.1 66.0 137.1
Net (income) loss attributable to noncontrolling interests
(0.4) (0.6) 0.3 0.9 0.2 (0.3) - (0.3)
Adjusted Net income attributable to Avient common
shareholders - continuing operations 62.6$ 61.3$ 45.4$ 36.1$ 205.4$ 70.8$ 66.0$ 136.8$
Adjusted earnings per share attributable to Avient
common shareholders - Diluted 0.68$ 0.66$ 0.49$ 0.39$ 2.23$ 0.77$ 0.72$ 1.48$
Weighted average diluted Shares 92.2 92.4 92.2 92.4 92.1 92.3 92.1 92.2
S E G M E N T D A T A R E C A S T F O R A V I E N T D I S T R I B U T I O N A S A D I S C O N T I N U E D
O P E R A T I O N
Avient Corporation 5
(In millions)
Q1 2021 Q2 2021 Q3 2021 Q4 2021 2021 YTD Q1 2022 Q2 2022 2022 YTD
Sales:
Color, Additives and Inks 609.3$ 624.4$ 586.6$ 581.3$ 2,401.6$ 649.5$ 649.1$ 1,298.6$
Specialty Engineered Materials 214.7 238.9 231.7 226.3 911.6 243.1 242.3 485.4
Corporate and Eliminations 2.0 1.2 (0.3) (0.5) 2.4 (0.4) (0.4) (0.8)
Sales 826.0 864.5 818.0 807.1 3,315.6 892.2 891.0 1,783.2
Gross Margin:
Color, Additives and Inks 197.5$ 193.4$ 172.1$ 164.5$ 727.5$ 192.1$ 193.4$ 385.5$
Specialty Engineered Materials 63.1 68.1 61.4 58.3 250.9 68.4 66.0 134.4
Corporate and Eliminations 2.5 (12.9) (17.9) (6.2) (34.5) (6.1) 1.5 (4.6)
Gross Margin 263.1 248.6 215.6 216.6 943.9 254.4 260.9 515.3
Se lling and Administrative Expense :
Color, Additives and Inks 108.7$ 107.1$ 105.3$ 103.3$ 424.4$ 97.6$ 99.8$ 197.4$
Specialty Engineered Materials 30.5 32.3 31.4 31.2 125.4 30.1 30.8 60.9
Corporate and Eliminations 29.5 26.8 26.1 31.9 114.3 24.5 30.2 54.7
Selling and Administrative Expense 168.7 166.2 162.8 166.4 664.1 152.2 160.8 313.0
Operating Income:
Color, Additives and Inks 88.8$ 86.3$ 66.8$ 61.2$ 303.1$ 94.5$ 93.6$ 188.1$
Specialty Engineered Materials 32.6 35.8 30.0 27.1 125.5 38.3 35.2 73.5
Corporate and Eliminations (27.0) (39.7) (44.0) (38.1) (148.8) (30.6) (28.7) (59.3)
Operating Income 94.4 82.4 52.8 50.2 279.8 102.2 100.1 202.3
Earnings Be fore Interest, Taxes,
Depreciation and Amortization (EBITDA):
Color, Additives and Inks 116.2$ 111.6$ 93.4$ 87.6$ 408.8$ 120.5$ 119.5$ 240.0$
Specialty Engineered Materials 40.4 43.9 37.9 35.1 157.3 46.1 42.9 89.0
Corporate and Eliminations (25.3) (39.5) (41.9) (34.6) (141.3) (26.8) (26.0) (52.8)
Other income (expense) 1.6 1.1 1.6 (5.3) (1.0) (0.6) 1.6 1.0
EBITDA 132.9 117.1 91.0 82.8 423.8 139.2 138.0 277.2
N O N - G A A P R E C O N C I L I A T I O N S F O R R E C A S T H I S T O R I C A L R E S U L T S
Avient Corporation 6
(In millions, except per share data)
Avie nt
Special
Items
Adjuste d
Avient Avient
Special
Items
Adjusted
Avient Avient
Special
Items
Adjusted
Avient Avient
Special
Items
Adjusted
Avient Avient
Special
Items
Adjusted
Avie nt
Sales $ 826.0 $ - $ 826.0 $ 864.5 $ - $ 864.5 $ 818.0 $ - $ 818.0 $ 807.1 $ - $ 807.1 $ 3,315.6 $ - $ 3,315.6
Gross margin 263.1 (2.2) 260.9 248.6 12.6 261.2 215.6 17.3 232.9 216.6 5.9 222.5 943.9 33.6 977.5
Selling and administrative expense 168.7 (4.6) 164.1 166.2 (1.6) 164.6 162.8 (2.7) 160.1 166.4 (5.3) 161.1 664.1 (14.2) 649.9
Operating income 94.4 2.4 96.8 82.4 14.2 96.6 52.8 20.0 72.8 50.2 11.2 61.4 279.8 47.8 327.6
Interest expense, net (19.3) - (19.3) (19.5) - (19.5) (19.0) - (19.0) (17.5) - (17.5) (75.3) - (75.3)
Other income (expense), net 1.6 - 1.6 1.1 - 1.1 1.6 (0.1) 1.5 (5.3) 9.4 4.1 (1.0) 9.3 8.3
Income taxes (16.3) 0.2 (16.1) (13.8) (2.5) (16.3) (2.0) (8.2) (10.2) (16.2) 3.4 (12.8) (48.3) (7.1) (55.4)
Net income (loss) attributable to noncontrolling
interests
(0.4) - (0.4) (0.6) - (0.6) 0.3 - 0.3 0.9 - 0.9 0.2 - 0.2
Net income from continuing operations attributable
to Avient shareholders
$ 60.0 $ 2.6 $ 62.6 $ 49.6 $ 11.7 $ 61.3 $ 33.7 $ 11.7 $ 45.4 $ 12.1 $ 24.0 $ 36.1 $ 155.4 $ 50.0 $ 205.4
Net income / EPS $ 0.65 0.03 $ 0.68 $ 0.54 0.13 $ 0.66 $ 0.37 0.13 $ 0.49 $ 0.13 $ 0.26 $ 0.39 $ 1.69 0.54 $ 2.23
Weighted-average diluted shares 92.2 92.2 92.2 92.4 92.4 92.4 92.2 92.2 92.2 92.4 92.4 92.4 92.1 92.1 92.1
Three Months Ended
December 31, 2021
Year Ended
December 31, 2021
Three Months Ended
March 31, 2021
Three Months Ended
June 30, 2021
Three Months Ended
September 30, 2021
N O N - G A A P R E C O N C I L I A T I O N S F O R R E C A S T H I S T O R I C A L R E S U L T S
Avient Corporation 7
(In millions, except per share data)
Avient
Special
Items
Adjusted
Avient Avient
Special
Items
Adjusted
Avient Avient
Special
Items
Adjusted
Avient
Sales $ 892.2 $ - $ 892.2 $ 891.0 $ - $ 891.0 $ 1,783.2 $ - $ 1,783.2
Gross margin 254.4 5.8 260.2 260.9 (2.0) 258.9 515.3 3.8 519.1
Selling and administrative expense 152.2 (0.9) 151.3 160.8 (3.8) 157.0 313.0 (4.7) 308.3
Operating income 102.2 6.7 108.9 100.1 1.8 101.9 202.3 8.5 210.8
Interest expense, net (16.9) - (16.9) (16.2) - (16.2) (33.1) - (33.1)
Other (expense) income, net (0.6) (0.1) (0.7) 1.6 (0.9) 0.7 1.0 (1.0) 0.0
Income taxes (20.0) (0.2) (20.2) (22.7) 2.3 (20.4) (42.7) 2.1 (40.6)
Net income attributable to noncontrolling interests (0.3) - (0.3) - - - (0.3) - (0.3)
Net income from continuing operations attributable
to Avient shareholders
$ 64.4 $ 6.4 $ 70.8 $ 62.8 $ 3.2 $ 66.0 $ 127.2 $ 9.6 $ 136.8
Net income / EPS $ 0.70 0.07 $ 0.77 $ 0.68 0.03 $ 0.72 $ 1.38 0.10 1.48
Weighted-average diluted shares 92.3 92.3 92.3 92.1 92.1 92.1 92.2 92.2 92.2
Three Months Ended
March 31, 2022
Three Months Ended
June 30, 2022
Six Months Ended
June 30, 2022
N O N - G A A P R E C O N C I L I A T I O N S F O R R E C A S T A D J U S T E D E B I T D A
Avient Corporation 8
(In millions)
EBITDA Reconciliation Q1 2021 Q2 2021 Q3 2021 Q4 2021 YTD 2021 Q1 2022 Q2 2022 YTD 2022
Net income from continuing operations – GAAP 60.4$ 50.2$ 33.4$ 11.2$ 155.2$ 64.7$ 62.8$ 127.5$
Income tax expense 16.3 13.8 2.0 16.2 48.3 20.0 22.7 42.7
Interest expense, net 19.3 19.5 19.0 17.5 75.3 16.9 16.2 33.1
Depreciation and amortization from continuing operations 36.9 33.6 36.6 37.9 145.0 37.6 36.3 73.9
EBITDA 132.9 117.1 91.0 82.8 423.8 139.2 138.0 277.2
Special items, before tax 2.4 14.2 19.9 20.6 57.1 6.6 0.9 7.5
Depreciation and amortization included in special items (0.6) 1.4 (0.9) (1.6) (1.7) (2.1) (1.1) (3.2)
Adjusted EBITDA 134.7$ 132.7$ 110.0$ 101.8$ 479.2$ 143.7$ 137.8$ 281.5$
S U M M A R Y O F S P E C I A L I T E M S
Avient Corporation 9
(In millions)
Q1 2021 Q2 2021 Q3 2021 Q4 2021 2021 YTD Q1 2022 Q2 2022 2022 YTD
Cost of sales:
Restructuring costs, including accelerated depreciation (1.8)$ (1.5)$ (5.3)$ (6.0)$ (14.6)$ (4.4)$ (2.6)$ (7.0)$
Environmental remediation costs (0.5) (12.5) (9.4) (0.5) (22.9) (2.0) (3.0) (5.0)
Reimbursement of previously incurred environmental costs 4.5 - - - 4.5 0.6 7.6 8.2
Acquisition related adjustments - 1.4 (2.6) 0.6 (0.6) - - -
Impact on cost of sales 2.2 (12.6) (17.3) (5.9) (33.6) (5.8) 2.0 (3.8)
Selling and administrative expense:
Restructuring, legal and other (1.3) (1.4) - (4.2) (6.9) 2.0 (1.7) 0.3
Acquisition/divestiture related costs (3.3) (0.2) (2.7) (1.1) (7.3) (2.9) (2.1) (5.0)
Impact on selling and administrative expense (4.6) (1.6) (2.7) (5.3) (14.2) (0.9) (3.8) (4.7)
Impact on operating income (2.4) (14.2) (20.0) (11.2) (47.8) (6.7) (1.8) (8.5)
Other income, net - - 0.1 (9.4) (9.3) 0.1 0.9 1.0
Impact on income before income taxes (2.4) (14.2) (19.9) (20.6) (57.1) (6.6) (0.9) (7.5)
Income tax benefit on above special items 0.9 3.4 4.6 4.1 13.0 1.7 0.2 1.9
Tax adjustments (1.1) (0.9) 3.6 (7.5) (5.9) (1.5) (2.5) (4.0)
Impact of special items on net income (2.6)$ (11.7)$ (11.7)$ (24.0)$ (50.0)$ (6.4)$ (3.2)$ (9.6)$
https://www.avient.com/sites/default/files/2024-07/CCG Application Snapshot Evoluscend Mold Release_Final.pdf
PowerPoint Presentation
M E D I C A L C O N N E C T O R S
• Ongoing production with no change to regular set up
• Excellent processing and demolding performance
• Color stability during processing
• Excellent chemical and impact resistance
• Enabled efficient ongoing production rates without
changing any processing parameters
• Safeguarded color stability and transparency
during processing for optimal aesthetics
• Ensured regulatory requirements for
biocompatible ISO109931 and FDA were met
• Provided a solution effective across a range of
high-temperature polymers, including PEEK,
PPSU, PES, PSU, PEI, LCP, and PPS
Colorant Chromatics Evoluscend non-
PFAS* high-temperature polymer mold release
additive
KEY REQUIREMENTS WHY AVIENT
AVIENT SOLUTION
PRODUCTIVITY + REGULATORY
LEARN MORE
E L E C T R I C A L
C O M P O N E N T O E M
(*) A non-PFAS additive manufactured without non-intentionally added (NIA) PFAS or PTFE.
(*) manufactured without intentionally added PFAS and without PTFE
(1) refers to sulfone products only
https://www.avient.com/products/polymer-additives/processing-enhancement-additives/colorant-chromatics-evoluscend-non-pfas-high-temperature-mold-release-additive
Slide Number 1
https://www.avient.com/sites/default/files/2021-01/mevopur-laser-welding-for-ivd-case-study-brief.pdf
G E N O M I C D I AG N O S T I C
D E V I C E M A N U FAC T U R E R
I N - V I T R O D I A G N O S T I C ( I V D ) D E V I C E
MEVOPURTM Laser-Transmitting and Laser-Absorbing
Pre-color Solution
AV I E N T S O L U T I O N
• Customized solutions - Quality-by-Design (QdB) approach
• Optimized pigment / additive selection – good distribution in
final part minimizes welding failure
• Mitigated contamination and extractable risk on incoming raw
material with control based on fingerprinting
• Ensured uninterrupted supply from multiple ISO13485-2016
certified sites
• Minimized risk of change with change control agreements
W H Y AV I E N T
K E Y R E Q U I R E M E N T S
P R O D U C T I V I T Y & Q U A L I T Y
• Good weldability, low rejection rate
• Solutions in wide range of polymers, colors and
transparency
• Pre-tested ingredients to biocompatibility and
extractable metals
L E A R N M O R E
https://www.avient.com/products/polymer-additives/performance-enhancement-additives/mevopur-functional-additives
https://www.avient.com/sites/default/files/2020-10/investing-in-avient.pdf
W H AT W E D O : M AT E R I A L S C I E N C E
6
CUSTOM
FORMULATION
We sell solutions not commodities.
D
is
t.
)
R
P
M
K
W
R
P
P
G
F
U
L
G
C
P
F
M
C
IF
F
H
X
L
H
U
N
F
O
E
E
M
N
E
C
L
S
C
L
K
R
A
A
S
H
C
E
G
R
A
A
L
B
As a specialty formulator, we don’t
require significant capital
investment, as compared to the
base resin raw material suppliers
we purchase from.
Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA
Source: Capital IQ market data as of August 24, 2020
Median: 84% Median: 75%
H I G H F R E E C A S H F L OW
C O N V E R S I O N
3.1x
2.6x
0.5x
1.9x
2.8x
3.1x
4.5x
-0.1x
1.8x
1.9x
2.2x 2.3x
2.4x
2.9x 3.0x 3.0x
3.2x
3.4x 3.4x
3.8x 3.9x
4.8x
A
vi
e
n
t
(2
0
P
F
)
A
vi
e
n
t
(2
1
E
)
G
C
P
P
P
G
R
P
M
K
W
R
F
U
L
S
C
L
B
N
R
H
U
N
E
C
L
C
E
F
M
C
A
S
H
H
X
L
E
M
N
G
R
A
A
L
B
IF
F
U
N
V
R
K
R
A
F
O
E
Net Debt / 2021E EBITDA (1)
We typically operate at 2.5–3.0x net
debt to EBITDA.
https://www.avient.com/sites/default/files/2020-11/investing-in-avient_0.pdf
W H AT W E D O : M AT E R I A L S C I E N C E
6
CUSTOM
FORMULATION
We sell solutions not commodities.
D
is
t.
)
R
P
M
K
W
R
P
P
G
F
U
L
A
V
Y
G
C
P
F
M
C
IF
F
H
X
L
H
U
N
F
O
E
E
M
N
E
C
L
S
C
L
K
R
A
A
S
H
C
E
G
R
A
A
L
B
Median: 5%Median: 3%
Avient Specialty
Formulators
Other
Chemical/Specialty
Companies
Free Cash Flow Conversion (1)
2021E (%)
Being asset light helps us to generate
strong free cash flow that is in line
with specialty formulators.
Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA
Source: Bloomberg market data as of November 9, 2020
Median: 82% Median: 73%
H I G H F R E E C A S H F LOW
C O N V E R S I O N
83
86 85 85
80 78
58
88
83 81 79 77 76 73 73 72 72
67
64 63 60
6
A
v
ie
n
t
K
W
R
R
P
M
P
P
G
F
U
L
A
V
Y
G
C
P
F
M
C
IF
F
U
N
V
R
B
N
R
E
M
N
E
C
L
C
E
H
X
L
F
O
E
A
S
H
G
R
A
H
U
N
K
R
A
S
C
L
A
L
B
Net Debt / 2021E EBITDA (1)
We typically operate at 2.5–3.0x net
debt to EBITDA.
https://www.avient.com/sites/default/files/2021-10/avnt-q3-2021-earnings-presentation_0.pdf
D
is
t.
)
K
W
R
P
P
G
A
V
Y
F
U
L
R
P
M
G
C
P
F
M
C
H
X
L
H
U
N
E
C
L
A
S
H
E
M
N
C
E
S
C
L
Source: Peer data per Bloomberg market data as of October 25, 2021
Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M)
Avient Specialty
Formulators
Other
Chemical/Specialty
Companies
Free Cash Flow Conversion (1)
2021E (%)
Being asset light helps us to generate
strong free cash flow that is in line
with specialty formulators.
Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA
H I G H F R E E C A S H F L OW
C O N V E R S I O N
Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M)
Source: Peer data per Bloomberg market data as of October 25, 2021
86
92
85
82
79
77
74
89
83 82
80 79 79 78 78
72
33
A
vi
e
n
t
K
W
R
P
P
G
A
V
Y
F
U
L
R
P
M
G
C
P
F
M
C
U
N
V
R
C
E
H
X
L
B
N
R
A
S
H
E
C
L
E
M
N
H
U
N
S
C
L
A
L
B
(12)
Source: Peer data per Bloomberg market data as of October 25, 2021
Total Enterprise Value / 2021E EBITDA
Our current valuation with updated
guidance implies an EBITDA multiple
that is below specialty formulator
peers and the median of other
selected chemical / specialty
companies.
With the Clariant Color business
acquisition and divestment of the
PP&S business, our exposure is now
concentrated in less-cyclical and
high-growth markets, with increased
geographic diversification and a more
specialized portfolio that can
significantly expand EBITDA margins.
24
Avient reflects 2021 estimated EBITDA of $580M
O U R VA LUATI O N V E R S U S P E E R S
Avient Specialty
Formulators
Other
Chemical/Specialty
Companies
11.0
18.3
16.3
15.4
14.5
11.6 11.1
36.2
28.0
24.9
13.0
11.5 11.3
10.0
9.2 8.8
7.7
6.7
A
vi
e
n
t
K
W
R
P
P
G
A
V
Y
R
P
M
F
U
L
G
C
P
A
L
B
H
X
L
E
C
L
A
S
H
F
M
C
B
N
R
S
C
L
U
N
V
R
E
M
N
C
E
H
U
N
S U M M A RY: W H Y I N V E S T I N AV I E N T ?
https://www.avient.com/sites/default/files/2021-11/avnt-november-investor-meetings.pdf
W H AT W E D O : M AT E R I A L S C I E N C E
4
CUSTOM
FORMULATION
We sell solutions not commodities.
D
is
t.
)
K
W
R
P
P
G
A
V
Y
F
U
L
R
P
M
G
C
P
F
M
C
H
X
L
H
U
N
E
C
L
A
S
H
E
M
N
C
E
S
C
L
Source: Peer data per Bloomberg market data as of November 8, 2021
Avient reflects 2021 estimated revenue of $4,750M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M)
Avient Specialty
Formulators
Other
Chemical/Specialty
Companies
Free Cash Flow Conversion (1)
2021E (%)
Being asset light helps us to generate
strong free cash flow that is in line
with specialty formulators.
Free cash flow conversion calculated as (EBITDA – Capex) / EBITDA
H I G H F R E E C A S H F L OW
C O N V E R S I O N
Avient reflects 2021 estimated EBITDA of $580M and estimated CAPEX of $80M (excludes one-time synergy capture CAPEX of $20M)
Source: Peer data per Bloomberg market data as of November 8, 2021
86
93
85
83
79
77 75
89
85 83 81 79 79 78 77
74
25
A
vi
e
n
t
K
W
R
P
P
G
A
V
Y
F
U
L
R
P
M
G
C
P
F
M
C
U
N
V
R
C
E
B
N
R
H
X
L
A
S
H
E
C
L
E
M
N
H
U
N
S
C
L
A
L
B
(10)
Source: Peer data per Bloomberg market data as of November 8, 2021
Total Enterprise Value / 2021E EBITDA
Our current valuation with updated
guidance implies an EBITDA multiple
that is below many of our specialty
formulator peers.
https://www.avient.com/sites/default/files/2020-07/case-study-one-pager-therma-tech-led-light-heat-exchanger.pdf
© 2019, All Right Reserved
Avient Corporation, 33587 Walker Road, Avon Lake, Ohio USA 44012
LED LIGHT
MANUFACTURER
H E A T E X C H A N G E R F O R A N
E L E C T R O N I C C I R C U I T B O A R D
• Looking to replace aluminum
• Reduce corrosion
• Light weighting
• Eliminated the effects of corrosion
• Provided a lightweight alternative to aluminium
• Redesigned the part for easier processing and
further weight reduction
• Enabled the customer to take a new, innovative
product in to the market
Therma-Tech™ Thermally Conductive Formulation
KEY REQUIREMENTS WHY AVIENT?
https://www.avient.com/sites/default/files/2023-03/Onflex-Cell Pack Cooling Tube-Application Snapshot.pdf
AVIENT SOLUTION
V E H I C L E B AT T E RY
M A N U FA C T U R E R
C E L L P A C K C O O L I N G T U B E
• Comply with ISO 3384-1:2011 for TPE compression set
• Comply with ISO 11359-2:1999 standard for linear thermal
expansion
• Good ethanediol resistance
• Good sealing performance
• Customized a Shore 60A hardness TPE
formulation with good physical property
retention
• Achieved good compression set and bonding
performance with PA12
• Qualified thermal expansion by customer
• Provided excellent ethanediol resistance under
both low and high temperature conditions
KEY REQUIREMENTS
CHEMICAL RESISTANCE + SEALING
LEARN MORE
OnFlex™ TPE Custom Formulation
Copyright © 2023, Avient Corporation.